These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9192768)

  • 1. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
    Hornick JL; Khawli LA; Hu P; Lynch M; Anderson PM; Epstein AL
    Blood; 1997 Jun; 89(12):4437-47. PubMed ID: 9192768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo.
    Funakoshi S; Hirano A; Beckwith M; Asai O; Jorgensen G; Tian Z; Hornick JL; Hu P; Khawli LA; Epstein AL; Longo DL; Murphy WJ
    Blood; 1997 Oct; 90(8):3160-6. PubMed ID: 9376598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes.
    Ottonello L; Morone P; Dapino P; Dallegri F
    Blood; 1996 Jun; 87(12):5171-8. PubMed ID: 8652830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
    Fukuda M; Horibe K; Furukawa K
    Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
    Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: intervention of FcgammaRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins.
    Ottonello L; Epstein AL; Dapino P; Barbera P; Morone P; Dallegri F
    Blood; 1999 May; 93(10):3505-11. PubMed ID: 10233903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake.
    Hu P; Hornick JL; Glasky MS; Yun A; Milkie MN; Khawli LA; Anderson PM; Epstein AL
    Cancer Res; 1996 Nov; 56(21):4998-5004. PubMed ID: 8895756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
    Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC
    Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
    Flieger D; Renoth S; Beier I; Sauerbruch T; Schmidt-Wolf I
    Cell Immunol; 2000 Aug; 204(1):55-63. PubMed ID: 11006018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells.
    Chan CH; Blazar BR; Eide CR; Kreitman RJ; Vallera DA
    Blood; 1995 Oct; 86(7):2732-40. PubMed ID: 7670112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of BCL-1 murine B-cell leukemia with recombinant cytokines. Comparative analysis of the anti-leukemic potential of interleukin 1 beta (IL-1 beta), interleukin 2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), and their combination.
    Chelstrom LM; Finnegan D; Uckun FM
    Leuk Lymphoma; 1992 May; 7(1-2):79-86. PubMed ID: 1282065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction, expression, and characterization of anticarcinoma sFv fused to IL-2 or GM-CSF.
    Zhao L; Rai SK; Grosmaire LS; Ledbetter JA; Fell HP
    J Hematother Stem Cell Res; 1999 Aug; 8(4):393-9. PubMed ID: 10634177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
    Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
    Leuk Lymphoma; 1994 Dec; 16(1-2):79-88. PubMed ID: 7535143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions.
    Wen Q; Xiong W; He J; Zhang S; Du X; Liu S; Wang J; Zhou M; Ma L
    J Transl Med; 2016 Feb; 14():41. PubMed ID: 26850448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human/mouse chimeric monoclonal antibody against intercellular adhesion molecule-1 for tumor radioimmunoimaging.
    Yamamura M; Hinoda Y; Sasaki S; Tsujisaki M; Oriuchi N; Endo K; Imai K
    Jpn J Cancer Res; 1996 Apr; 87(4):405-11. PubMed ID: 8641973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.